000166490 001__ 166490
000166490 005__ 20240229133521.0
000166490 0247_ $$2doi$$a10.1007/s00259-020-05137-7
000166490 0247_ $$2pmid$$apmid:33336264
000166490 0247_ $$2ISSN$$a0340-6997
000166490 0247_ $$2ISSN$$a1432-105X
000166490 0247_ $$2ISSN$$a1619-7070
000166490 0247_ $$2ISSN$$a1619-7089
000166490 0247_ $$2altmetric$$aaltmetric:96319285
000166490 037__ $$aDKFZ-2020-02933
000166490 041__ $$aeng
000166490 082__ $$a610
000166490 1001_ $$0P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aSachpekidis, Christos$$b0$$eFirst author$$udkfz
000166490 245__ $$aInterim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.
000166490 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2021
000166490 3367_ $$2DRIVER$$aarticle
000166490 3367_ $$2DataCite$$aOutput Types/Journal article
000166490 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1623236501_6854
000166490 3367_ $$2BibTeX$$aARTICLE
000166490 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166490 3367_ $$00$$2EndNote$$aJournal Article
000166490 500__ $$a#EA:E060#LA:E060# / 2021 Jun;48(6):1932-1943
000166490 520__ $$aIn an attempt to identify biomarkers that can reliably predict long-term outcomes to immunotherapy in metastatic melanoma, we investigated the prognostic role of [18F]FDG PET/CT, performed at baseline and early during the course of anti-PD-1 treatment.Twenty-five patients with stage IV melanoma, scheduled for treatment with PD-1 inhibitors, were enrolled in the study (pembrolizumab, n = 8 patients; nivolumab, n = 4 patients; nivolumab/ipilimumab, 13 patients). [18F]FDG PET/CT was performed before the start of treatment (baseline PET/CT) and after the initial two cycles of PD-1 blockade administration (interim PET/CT). Seventeen patients underwent also a third PET/CT scan after administration of four cycles of treatment. Evaluation of patients' response by means of PET/CT was performed after application of the European Organization for Research and Treatment of Cancer (EORTC) 1999 criteria and the PET Response Evaluation Criteria for IMmunoTherapy (PERCIMT). Response to treatment was classified into 4 categories: complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease (PMD). Patients were further grouped into two groups: those demonstrating metabolic benefit (MB), including patients with SMD, PMR, and CMR, and those demonstrating no MB (no-MB), including patients with PMD. Moreover, patterns of [18F]FDG uptake suggestive of radiologic immune-related adverse events (irAEs) were documented. Progression-free survival (PFS) was measured from the date of interim PET/CT until disease progression or death from any cause.Median follow-up from interim PET/CT was 24.2 months (19.3-41.7 months). According to the EORTC criteria, 14 patients showed MB (1 CMR, 6 PMR, and 7 SMD), while 11 patients showed no-MB (PMD). Respectively, the application of the PERCIMT criteria revealed that 19 patients had MB (1 CMR, 6 PMR, and 12 SMD), and 6 of them had no-MB (PMD). With regard to PFS, no significant difference was observed between patients with MB and no-MB on interim PET/CT according to the EORTC criteria (p = 0.088). In contrary, according to the PERCIMT criteria, patients demonstrating MB had a significantly longer PFS than those showing no-MB (p = 0.045). The emergence of radiologic irAEs (n = 11 patients) was not associated with a significant survival benefit. Regarding the sub-cohort undergoing also a third PET/CT, 14/17 patients (82%) showed concordant responses and 3/17 (18%) had a mismatch of response assessment between interim and late PET/CT.PET/CT-based response of metastatic melanoma to PD-1 blockade after application of the recently proposed PERCIMT criteria is significantly correlated with PFS. This highlights the potential ability of [18F]FDG PET/CT for early stratification of response to anti-PD-1 agents, a finding with possible significant clinical and financial implications. Further studies including larger numbers of patients are necessary to validate these results.
000166490 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000166490 588__ $$aDataset connected to CrossRef, PubMed,
000166490 650_7 $$2Other$$aAnti-PD-1 therapy
000166490 650_7 $$2Other$$aEORTC criteria
000166490 650_7 $$2Other$$aImmunotherapy
000166490 650_7 $$2Other$$aInterim [18F]FDG PET/CT
000166490 650_7 $$2Other$$aMetastatic melanoma
000166490 650_7 $$2Other$$aPERCIMT criteria
000166490 650_7 $$2Other$$aTreatment response evaluation
000166490 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b1$$udkfz
000166490 7001_ $$0P:(DE-He78)96ac0342a3ccf9553e3d4c9da9b821b0$$aPan, Leyun$$b2$$udkfz
000166490 7001_ $$0P:(DE-He78)d3448cb2463ac4b543632a05e5b50f9d$$aPapamichail, Dimitrios$$b3$$udkfz
000166490 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b4$$udkfz
000166490 7001_ $$aHassel, Jessica C$$b5
000166490 7001_ $$0P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDimitrakopoulou-Strauss, Antonia$$b6$$eLast author$$udkfz
000166490 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-020-05137-7$$n6$$p1932-1943$$tEuropean journal of nuclear medicine and molecular imaging$$v48$$x1619-7089$$y2021
000166490 909CO $$ooai:inrepo02.dkfz.de:166490$$pVDB
000166490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000166490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000166490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)96ac0342a3ccf9553e3d4c9da9b821b0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000166490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d3448cb2463ac4b543632a05e5b50f9d$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000166490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000166490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000166490 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000166490 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000166490 9141_ $$y2021
000166490 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2020-08-29$$wger
000166490 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-29
000166490 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-29
000166490 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-29
000166490 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-29
000166490 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-29
000166490 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-08-29
000166490 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-29
000166490 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-08-29
000166490 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-29
000166490 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-29
000166490 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2018$$d2020-08-29
000166490 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2018$$d2020-08-29
000166490 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000166490 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000166490 980__ $$ajournal
000166490 980__ $$aVDB
000166490 980__ $$aI:(DE-He78)E060-20160331
000166490 980__ $$aI:(DE-He78)C060-20160331
000166490 980__ $$aUNRESTRICTED